Background:Lung adenocarcinoma (LUAD) is a major type of lung cancer
worldwide, and under the pandemic coronavirus disease 2019 (COVID-19), its cancer
burden is enlarged. This study aimed to explore potential drug targets and potential drugs
for developing effective treatments for patients with both lung cancer and COVID-19.Methods:The interaction network of molecule compounds-target genes was constructed
based on Traditional Chinese Medicines (TCMs) and gene expression data from public
databases. The potential effectiveness of drugs was analyzed by molecular docking and
molecular dynamics simulation. Western blot, transfection assay, Immunohistochemistry
(IHC) staining, and flow cytometry were performed to investigate the function of
HSP90AA1 in LUAD cells.Result:Eight target genes (GSK3B, HMOX1, HSP90AA1, ICAM1, MAPK1, PLAU,
RELA and TNFSF15.) were identified, and two of them (HSP90AA1 and RELA) were
significantly associated with LUAD prognosis. Luteolin was discovered to bind with
HSP90AA1. Moreover, in vitro cell experiments demonstrated that HSP90AA1 had higher
expression in A549 cells, promoted cell viability and suppressed apoptosis in A549
cells and H1299 cells.Conclusion:HSP90AA1 was a target gene for further designing effective drugs for LUAD
patients. Luteolin was a potential drug for treating patients with both LUAD and
COVID-19.